26 Oct 2026 Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers Investors | Therapeutics
23 Oct 2026 Avacta Highlights pre|CISION Platform Data and Ongoing FOCUS-01 Trial Design with FAP-Exd (AVA6103) Investors | Therapeutics
14 Oct 2026 Avacta to Present Progression Free Survival Data on Faridoxorubicin (AVA6000) and the FOCUS-01 (AVA6103) Trial Design at the ESMO 2026 Congress Investors | Therapeutics
25 Sep 2026 The pre|CISION® Platform Wins Research and Development Achievement Award from Pharma Industry Awards UK 2026 Investors | Therapeutics
25 Sep 2026 The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer Therapeutics
16 Sep 2026 Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial Investors | Therapeutics
25 Jun 2026 Avacta Reports Platform-Validating Data with Faridoxorubicin during BIO International Conference Investors | Therapeutics
25 Jun 2026 Avacta Announces U.S. FDA Agreement on Pivotal Trial Design for AVA6000 in Patients with Salivary Gland Cancer Investors | Therapeutics